
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

Numares AG cashes in €20m from EIB
The European Investment Bank (EIB) announced to invest up to €20m "quasi-equity" loan in German Numares Health AG. The Regensburg-based...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

AMsilk scaling up through Evonik collaboration
Just one week after AMSilk inked a collaboration agreement on protein engineering of its silk protein to target new applications with Brain Biotech...

Ethris inks €15m deal with Indian Ciplas
The investment is aimed at establishing a long-term strategic partnership until the end of Q1/2023 between Cipla and Ethris for the development of...

500 experts at the 7th AMR Conference in Basel
That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel from March 16-17....

Macomics licences macrophage modulator to Ono
Whether Macomics Ltd nor Ono Pharmaceuticals Co Ltd disclosed any financial details about the deal under which Ono has the option to licence an...